GeneNews to conduct joint project funded by MYR 5 million grant from
Malaysian government

    
    - Malaysian Ministry of Health provides grant to develop blood-based
    diagnostic tests for liver cancer, Hepatitis B and nasopharyngeal
    cancer -
    

TORONTO, April 29 /CNW/ - GeneNews Limited (TSX: GEN), a company focused on developing blood-based biomarker tests for the early detection of diseases and personalized health management, today announced that it will undertake a two-year joint project to develop blood-based diagnostic tests for liver cancer, Hepatitis B and nasopharyngeal cancer based on their Sentinel Principle(TM) platform technology. The Malaysian Ministry of Health will provide a grant of MYR 5 million to support this work which will be executed by GeneNews (Malaysia) Sdn. Bhd., a subsidiary of GeneNews. Project funding was jointly announced by the Honourable Minister of Health for Malaysia Dato' Sri Liow Tiong Lai and the Director General of Health for Malaysia Tan Sri Datuk Dr. Haji Mohd Ismail Merican.

"Liver cancer, Hepatitis B - a liver disease that can result in liver cancer, and nasopharyngeal cancer - a cancer of the upper throat and nasal passages, are among the most significant causes of chronic disease and death in Asia," said Dr. C. C. Liew, Co-Founder and Chief Scientist of GeneNews. "Our project with the Malaysian Ministry of Health aims to develop blood-based, genomic diagnostic tests for the early detection and staging of these three diseases. This collaboration also gives GeneNews the opportunity to train select Malaysian Ministry of Health staff, contributing to their human capital development, and also adding depth to GeneNews' research and development expertise in Malaysia."

"In line with the strategic restructuring of our operations that was implemented last November, this research and development collaboration will allow us to develop additional tests based on our proprietary Sentinel Principle(TM) platform technology," said Dr. Heiner Dreismann, Lead Director and Interim CEO of GeneNews. "This joint project will benefit both the Malaysian government, which could drastically reduce the incidence of and health care expenses associated with these diseases, and GeneNews, through the expansion of our pipeline while we continue to focus on the North American and European commercialization of our ColonSentry(TM) test from our corporate headquarters in Canada."

    
    About GeneNews
    --------------
    

GeneNews is focused on the application of functional genomics to enable early diagnosis and personalized therapeutic intervention based on disease-specific biomarkers. The Company has developed a novel approach, the Sentinel Principle(TM), to detect and stage virtually any disease or medical condition from a simple blood sample. GeneNews is currently applying the Sentinel Principle(TM) in major areas with unmet clinical needs such as cancer, arthritis, cardiovascular disease and neurological disorders. GeneNews launched its first commercial product, ColonSentry(TM), a blood-based test to assess an individual's risk for colorectal cancer, in Canada in 2008. For more information on GeneNews and ColonSentry(TM), visit www.genenews.com or www.colonsentry.com.

This press release contains forward-looking statements, which reflect the Company's current expectations regarding future events. The forward-looking statements involve risks and uncertainties. Actual events could differ materially from those projected herein. Investors should consult the Company's ongoing quarterly filings and annual reports for additional information on risks and uncertainties relating to these forward-looking statements. The reader is cautioned not to rely on these forward-looking statements. The Company disclaims any obligation to update these forward-looking statements.

SOURCE GeneNews Limited

For further information: For further information: Casey Gurfinkel, (416) 815-0700 x 283, cgurfinkel@equicomgroup.com


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890